{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:58:21Z","timestamp":1696237101309},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.bpg.2012.09.008","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T05:11:26Z","timestamp":1354165886000},"page":"471-485","source":"Crossref","is-referenced-by-count":10,"title":["Second generation direct antivirals and the way to interferon-free regimens in chronic HCV"],"prefix":"10.1016","volume":"26","author":[{"given":"Heather","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morven","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5424","key":"10.1016\/j.bpg.2012.09.008_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.bpg.2012.09.008_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"issue":"30","key":"10.1016\/j.bpg.2012.09.008_bib3","doi-asserted-by":"crossref","first-page":"22725","DOI":"10.1074\/jbc.R110.125294","article-title":"Hepatitis C virus non-structural protein 3 [HCV NS3]: a multifunctional antiviral target","volume":"285","author":"Raney","year":"2010","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.bpg.2012.09.008_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","article-title":"Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus","volume":"18","author":"Morikawa","year":"2011","journal-title":"J Viral Hepat"},{"issue":"13","key":"10.1016\/j.bpg.2012.09.008_bib5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bpg.2012.09.008_bib6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bpg.2012.09.008_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bpg.2012.09.008_bib8","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2012.09.008_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","volume":"141","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib10","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(09)60012-X","article-title":"Results of a proof of concept study [C210] of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients","volume":"50","author":"Benhamou","year":"2009","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2012.09.008_bib11","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2012.09.008_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2012.09.008_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.bpg.2012.09.008_bib14","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.bpg.2012.09.008_bib15","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.bpg.2012.09.008_bib16","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.bpg.2012.09.008_bib17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60010-X","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"54","author":"Sullivan","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.008_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.008_bib19","series-title":"Hepatitis C: new drugs","author":"Lange","year":"2012"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib20","first-page":"1429A","article-title":"TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIb study","volume":"54","author":"Fried","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(12)60016-6","article-title":"TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon\/ribavirin treatment: final SVR24 results of the ASPIRE trial","volume":"56","author":"Zeuzem","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib22","first-page":"398A","article-title":"High sustained virologic response [SVR24] rates with response-guided danoprevir [DNV; RG7227] plus pegIFN \u03b1-2a [40KD] and ribavirin [P\/R] in treatment-naive HCV genotype 1 [G1] patients: results from the ATLAS study","volume":"54","author":"Terrault","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib23","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(12)61189-1","article-title":"Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir\/peg-IFN\u03b1-2A\/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis","volume":"56","author":"Everson","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2012.09.008_bib24","first-page":"S27","article-title":"SILEN C-3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa 2a and ribavirin [P\/R] in treatment naive patients with chronic genotype 1 HCV infection","volume":"54","author":"Dieterich","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2012.09.008_bib25","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0168-8278(11)60062-7","article-title":"Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates - results from SILEN-C1 in treatment-naive patients across different baseline factors","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib26","first-page":"1424A","article-title":"A phase 2B study of MK-7009 [vaniprevir] in patients with genotype 1 infection who have failed previous pegylated interferon and ribavirin treatment","volume":"54","author":"Lawitz","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib27","doi-asserted-by":"crossref","first-page":"S470","DOI":"10.1016\/S0168-8278(12)61199-4","article-title":"ABT-450\/ritonavir [ABT-450\/r] combined with pegylated interferon alpha-2a\/ribavirin [P\/R] after 3-day monotherapy in HCV genotype 1 [GT1]-Infected treatment-na\u00efve subjects: 12-week sustained virologic response [SVR12] and safety results","volume":"56","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2012.09.008_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2012.09.008_bib29","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.01317-07","article-title":"The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to non nucleoside polymerase or protease inhibitors","volume":"52","author":"McCown","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib30","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1016\/S0168-8278(12)61125-8","article-title":"ELECTRON: once daily PSI-7977 plus RBV in HCV GT1\/2\/3","volume":"56","author":"Gane","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib31","first-page":"472A","article-title":"PROTON: PSI-7977 & Peg\/RBV in treatment-na\u00efve patients with HCV GT1: sustained virologic response","volume":"54","author":"Lawitz","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib32","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(12)00243-7","article-title":"Atomic: 97% RVR for PSI-7977 plus PEG\/RBV \u00d7 12 week regimen in HCV GT1: an end to response guided therapy?","volume":"56","author":"Kowdley","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib33","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1016\/S0168-8278(11)61361-5","article-title":"First SVR data with the nucleoside analogue polymerase inhibitor mericitabine [RG7128] combined with peginterferon\/ribavirin in treatment-naive HCV G1\/4 patients: interim analysis from the JUMP-C trial","volume":"54","author":"Pockros","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib34","doi-asserted-by":"crossref","first-page":"S477","DOI":"10.1016\/S0168-8278(12)61217-3","article-title":"SVR12 among G1\/4 treatment-na\u00efve patients receiving mericitabine in combination with PEG-IFN\u03b1-2A\/RBV: Interim analysis from the JUMP-C study","volume":"56","author":"Pockros","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2012.09.008_bib35","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jac\/dkn085","article-title":"Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients","volume":"61","author":"Le Pogam","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib36","first-page":"486A","article-title":"High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and pegIFN\/ribavirin \u2013 the SOUND-C1 study","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib37","first-page":"1435A","article-title":"VX-222\/Telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-na\u00efve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis","volume":"54","author":"Nelson","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib38","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S0168-8278(11)60427-3","article-title":"Four-week treatment with GS-9256 and tegobuvir [GS-9190], \u00b1 RBV \u00b1 PEG, results in enhanced viral suppression on follow-up PEG\/RBV therapy, in genotype 1a\/1b HCV patients","volume":"54","author":"Foster","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib39","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/S0168-8278(11)60447-9","article-title":"A phase 2b trial comparing 24 to 48 weeks treatment with tegobuvir [GS-9190]\/PEG\/RBV to 48 weeks treatment with PEG.RBV for chronic genotype 1 HCV infection","volume":"54","author":"Lawitz","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib40","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/S0168-8278(12)61218-5","article-title":"ABT-072 or ABT-333 combined with pegylated interferon\/ribavirin after 3-day monotherapy in HCV genotype 1 [GT1]-Infected treatment-na\u00efve subjects: 12-week sustained virologic response [SVR12] and safety results","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib41","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61410-X","article-title":"12-week interferon-free regimen of ABT-450\/r\u00a0+\u00a0ABT-333\u00a0+\u00a0ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders","volume":"56","author":"Poordad","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2012.09.008_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.bpg.2012.09.008_bib43","doi-asserted-by":"crossref","first-page":"e1000032","DOI":"10.1371\/journal.ppat.1000032","article-title":"Regulation of hepatitis C virion production via phosphorylation of the NS5A protein","volume":"4","author":"Tellinghuisen","year":"2008","journal-title":"PLoS Pathog"},{"issue":"14","key":"10.1016\/j.bpg.2012.09.008_bib44","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1128\/JVI.00393-11","article-title":"Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner","volume":"85","author":"Foster","year":"2011","journal-title":"J Virol"},{"issue":"13","key":"10.1016\/j.bpg.2012.09.008_bib45","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1128\/JVI.02156-10","article-title":"Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III","volume":"85","author":"Kim","year":"2011","journal-title":"J\u00a0Virol"},{"issue":"7294","key":"10.1016\/j.bpg.2012.09.008_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bpg.2012.09.008_bib47","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib48","doi-asserted-by":"crossref","first-page":"S557","DOI":"10.1016\/S0168-8278(12)61426-3","article-title":"Confirmation that quadruple therapy with daclatasvir [NS5A inhibitor], asunaprevir [NS3 inhibitor] and Peginterferon\/Ribavirin results in a high rate of SVR4 in HCV genotype 1 null responders","volume":"56","author":"Lok","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib49","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/S0168-8278(11)61358-5","article-title":"Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN\/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders","volume":"54","author":"Lok","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib50","first-page":"474A","article-title":"BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV- genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results","volume":"54","author":"Hezode","year":"2011","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.bpg.2012.09.008_bib51","doi-asserted-by":"crossref","first-page":"e1000546","DOI":"10.1371\/journal.ppat.1000546","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"Kaul","year":"2009","journal-title":"PLoS Pathog"},{"issue":"20","key":"10.1016\/j.bpg.2012.09.008_bib52","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"Hanoulle","year":"2009","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.bpg.2012.09.008_bib53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in\u00a0vitro","volume":"43","author":"Paeshuyse","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2012.09.008_bib54","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients","volume":"49","author":"Flisiak","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib55","doi-asserted-by":"crossref","first-page":"S553","DOI":"10.1016\/S0168-8278(12)61416-0","article-title":"Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study","volume":"56","author":"Pawlotsky","year":"2012","journal-title":"J Hepatol"},{"issue":"5740","key":"10.1016\/j.bpg.2012.09.008_bib56","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bpg.2012.09.008_bib57","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1073\/pnas.1112263109","article-title":"Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex","volume":"109","author":"Shimakami","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.bpg.2012.09.008_bib58","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/emboj.2008.244","article-title":"MicroRNA-122 stimulates translation of hepatitis C virus RNA","volume":"27","author":"Henke","year":"2008","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.bpg.2012.09.008_bib59","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1073\/pnas.1016606108","article-title":"MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR","volume":"108","author":"Li","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib60","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(12)60072-5","article-title":"Final results - randomized, double-blind, placebo-controlled safety, anti-viral proof-of-concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment-naive patients with genotype 1 chronic HCV infection","volume":"56","author":"Reesink","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib61","first-page":"1436A","article-title":"Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpg.2012.09.008_bib62","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1016\/S0168-8278(12)61423-8","article-title":"Interferon free treatment with a combination of mericitabine and danoprevir with or without ribavirin in treatment-na\u00efve HCV genotype 1 infected patients","volume":"56","author":"Gane","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib63","doi-asserted-by":"crossref","first-page":"S560","DOI":"10.1016\/S0168-8278(12)61433-0","article-title":"Potent viral suppression with the all-oral combination of daclatasvir [NS5A inhibitor] and GS-7977 [nucleotide NS5B inhibitor], +\/\u2212 ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3","volume":"56","author":"Sulkowski","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib64","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(12)60027-0","article-title":"A 12-week interferon-free regimen of ABT-450r, ABT-072 and ribavirin was well tolerated and achieved sustained virological response in 91% of treatment-naive HCV IL28B-CC genotype-1 infected patients","volume":"56","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.008_bib65","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(12)60028-2","article-title":"Dual oral therapy with NS5A inhibitor daclatasvir [BMS-790052] and NS3 protease inhibitor asunaprevir [BMS-650032] in HCV genotype 1b-Infected null responders or patients ineligible\/intolerant to peginterferon\/ribavirin","volume":"56","author":"Suzuki","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.008_bib66","series-title":"HCV structure and viral replication","author":"Kupfer","year":"2012"},{"key":"10.1016\/j.bpg.2012.09.008_bib69","series-title":"The IDX-08C-004 investigator group a phase IIa study of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment-na\u00efve genotype 1 HCV-infected subjects","author":"Lalezari","year":"2010"},{"key":"10.1016\/j.bpg.2012.09.008_bib70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.24342","article-title":"Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1\u2013infected patients","volume":"54","author":"Wagner","year":"2011","journal-title":"Hepatology"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T03:28:51Z","timestamp":1540092531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691812000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1521691812000911"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2012.09.008","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}